Browse the evidence

Dysregulation of pathways involving class B1 receptors can lead to obesity and diabetes mellitus.

Addressing dysregulation in these pathways may be crucial for obesity and diabetes management.

More research is required to fully understand the contribution of RAMPs to obesity and diabetes.

Future studies should focus on RAMPs to clarify their roles in obesity and diabetes.

Advances in understanding molecular causes of rare genetic obesities have led to therapies targeting appetite regulation.

Practitioners should consider new therapies targeting appetite regulation for patients with rare genetic obesities.

Emerging therapeutic strategies are focusing on novel targets such as growth differentiation factor 15 (GDF15) and bile acid receptors including the farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5).

Practitioners should stay informed about these novel molecular targets for potential future therapies in obesity management.

GLP-1 receptor agonists can exist stably in patients for a long time, overcoming the short half-life of natural GLP-1.

Practitioners can expect longer-lasting effects from GLP-1 receptor agonists compared to natural GLP-1.

The effects of rifampicin on obesity are mediated through Sirt6.

Targeting Sirt6 may enhance the effectiveness of rifampicin in obesity treatment.

Novel drug candidates like dual amylin and calcitonin receptor agonists (DACRAs) have insulin-sensitizing properties through a weight-independent action.

DACRAs may offer new treatment options for improving insulin sensitivity.

The comparative bioavailability of semaglutide following oral administration (3 mg) relative to subcutaneous administration (0.25 mg) is 0.66%.

Practitioners should note the lower bioavailability of oral semaglutide compared to subcutaneous administration.

The pharmacokinetics of semaglutide was characterized following the administration of low subcutaneous and oral doses.

Understanding the pharmacokinetics can inform dosing strategies for semaglutide.

Molecular engineering strategies have advanced biologic therapies for diabetes by optimizing therapeutic stability, pharmacokinetics, and delivery.

Practitioners can leverage molecular engineering to enhance diabetes therapies.

Structural modifications such as amino acid substitutions and PEGylation enhance stability and extend half-life of diabetes therapeutics.

Incorporating these modifications can improve the efficacy of diabetes treatments.

Diabetes Mellitus (DM) is caused by interactions between multiple factors and triggers.

Understanding the multifactorial nature of DM can guide prevention and treatment strategies.

Numerous medications for diabetics have been developed to help alleviate the symptoms of hyperglycemia.

Practitioners can utilize a variety of medications to manage hyperglycemia in diabetic patients.

Some factors and mechanisms involved in DM development are controversial and have contradicting experimental results.

Awareness of controversial factors can inform research directions and clinical approaches.

iWAT injection of MPDA@TZP improved leptin resistance, beiging, lipid metabolism, mitochondrial activity, and branched-chain amino acid (BCAA) catabolism in iWAT.

Understanding these metabolic improvements can guide targeted therapies for obesity.

Defects in mitochondrial oxidative phosphorylation contribute to insulin resistance and β-cell apoptosis.

Addressing mitochondrial oxidative phosphorylation may improve insulin sensitivity.

Activation of the mitogen-activated protein kinase signalling cascade has been proposed as a possible mechanism involved in the regulation of many of the exercise-induced adaptations in skeletal muscle.

Understanding this mechanism can help in designing effective training programs.

The genetic risk score (GRS) was associated with incident coronary heart disease (CHD) across cohorts, with a relative risk (RR) of 1.59 (95% CI: 1.41-1.79) for the highest quintile compared to the lowest.

Genetic risk factors significantly contribute to the likelihood of developing CHD, highlighting the importance of genetic screening.

No significant findings emerged in White women, African American men, or for the 8-10 week outcomes or for waist-to-hip ratio adjusted for body mass index (WHRadjBMI).

Practitioners should be cautious in generalizing findings across different demographic groups.

Monogenic obesity is rare and caused by mutations in a single gene.

Recognizing the rarity of monogenic obesity can help in accurate diagnosis and treatment.

Tirzepatide is a GIP receptor and GLP-1 receptor agonist.

Understanding the mechanism can help in predicting the drug's effects and potential interactions.

Research priorities include genetic/epigenetic factors, brain-periphery communication, and environmental influences.

Understanding these factors can guide research and interventions in endocrine health.

There is a biologically plausible link between GLP-1 RAs and pathways central to periodontal inflammation and host response.

Understanding this link may guide future research on periodontal treatments.

The oleogel-in-oleogel system reduces in vitro digestibility by 17%–26% compared to control oleogels and up to 33% compared to single-component oleogels.

This system may help in reducing caloric intake from fats, aiding in obesity management.